| Anna Harmandarian, DDS | |
|
1609 Colorado Blvd, Los Angeles, CA 90041-1402 | |
| (323) 474-6212 | |
| (323) 474-6212 |
| Full Name | Anna Harmandarian |
|---|---|
| Gender | Female |
| Speciality | Dentist - General Practice |
| Location | 1609 Colorado Blvd, Los Angeles, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053516518 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 39273 (California) | Primary |
| Entity Name | Northeast Valley Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629079009 PECOS PAC ID: 3173517323 Enrollment ID: O20040412001067 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
According to a new report published this week, excess body weight is one of the major reasons behind cancers worldwide. The report written by scientists at the American Cancer Society (ACS) and published in the journal CA: A Cancer Journal for Clinicians shows that 3.9 percent of the cases of cancers were linked to excess body weight and this amounted to 544,300 cases in 2012.
Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna Harmandarian, DDS 1609 Colorado Blvd, Los Angeles, CA 90041 Ph: (323) 474-6212 | Anna Harmandarian, DDS 1609 Colorado Blvd, Los Angeles, CA 90041-1402 Ph: (323) 474-6212 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
According to a new report published this week, excess body weight is one of the major reasons behind cancers worldwide. The report written by scientists at the American Cancer Society (ACS) and published in the journal CA: A Cancer Journal for Clinicians shows that 3.9 percent of the cases of cancers were linked to excess body weight and this amounted to 544,300 cases in 2012.
Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise.
› Verified 5 days ago
Dr. Kyung A Lim, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 827 S Berendo St Apt 202, Los Angeles, CA 90005 Phone: 213-219-2530 | |
Sonia Khullar, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 132 S Vermont Avenue, Suite #210, Los Angeles, CA 90004 Phone: 213-389-2625 Fax: 213-389-4736 | |
Dr. William W Morgan, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 100 Ucla Medical Plz Ste 350, Los Angeles, CA 90095 Phone: 310-794-5750 | |
Dr. Clarice Law Eyre, DMD, MS Dentist Medicare: Not Enrolled in Medicare Practice Location: 100 Ucla Medical Plz Ste 350, Los Angeles, CA 90095 Phone: 310-794-5750 | |
Dr. Arjang Vahidnia, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 7162 Beverly Blvd, #543, Los Angeles, CA 90036 Phone: 310-443-3030 | |
Dr. Adrian Sanchez, Dentist Medicare: Not Enrolled in Medicare Practice Location: 6114 York Blvd, Suite C, Los Angeles, CA 90042 Phone: 323-255-6698 | |
Dr. Bindu Vasudevan Pillai, DDS Dentist Medicare: Medicare Enrolled Practice Location: 5207 Whittier Blvd, Los Angeles, CA 90022 Phone: 323-269-0266 |